The role of vascular endothelial growth factor and other endogenous interplayers in age-related macular degeneration
暂无分享,去创建一个
[1] N. Ferrara,et al. Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells. , 1989, Biochemical and biophysical research communications.
[2] A. Ho,et al. Foveolar choroidal blood flow in age-related macular degeneration. , 1998, Investigative ophthalmology & visual science.
[3] Xin-shu Dong,et al. Effects of endostatin on expression of vascular endothelial growth factor and its receptors and neovascularization in colonic carcinoma implanted in nude mice. , 2004, World journal of gastroenterology.
[4] W R Green,et al. CLINICOPATHOLOGIC CORRELATION OF DRUSEN AND RETINAL PIGMENT EPITHELIAL ABNORMALITIES IN AGE-RELATED MACULAR DEGENERATION , 2005, Retina.
[5] G. Polunin,et al. [Pathogenesis of age-related macular degeneration]. , 2006, Vestnik oftalmologii.
[6] K. Chalam,et al. Increased level of vascular endothelial growth factor in aqueous humor of patients with neovascular glaucoma. , 1998, Ophthalmology.
[7] H. Dvorak,et al. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. , 1983, Science.
[8] S. Seregard,et al. Immunohistochemical characterization of surgically removed subfoveal fibrovascular membranes , 1994, Graefe's Archive for Clinical and Experimental Ophthalmology.
[9] C. Grindle,et al. Ageing changes in Bruch's membrane and their functional implications. , 1978, Transactions of the ophthalmological societies of the United Kingdom.
[10] N. Bressler,et al. Clinicopathologic correlation of drusen and retinal pigment epithelial abnormalities in age-related macular degeneration. 1994. , 2005, Retina.
[11] I. Morita,et al. Vascular endothelial growth factor upregulates pigment epithelium-derived factor expression via VEGFR-1 in human retinal pigment epithelial cells. , 2003, Biochemical and biophysical research communications.
[12] S. Maxwell,et al. Matrix metalloproteinase-1 and -9 activation by plasmin regulates a novel endothelial cell-mediated mechanism of collagen gel contraction and capillary tube regression in three-dimensional collagen matrices. , 2001, Journal of cell science.
[13] William Arbuthnot Sir Lane,et al. Endostatin: An Endogenous Inhibitor of Angiogenesis and Tumor Growth , 1997, Cell.
[14] B. Olsen,et al. Localization of collagen XVIII and the endostatin portion of collagen XVIII in aged human control eyes and eyes with age-related macular degeneration. , 2004, Investigative ophthalmology & visual science.
[15] L. V. Johnson,et al. A potential role for immune complex pathogenesis in drusen formation. , 2000, Experimental eye research.
[16] Robert F Mullins,et al. A role for local inflammation in the formation of drusen in the aging eye. , 2002, American journal of ophthalmology.
[17] J. Folkman. Endogenous angiogenesis inhibitors , 2004, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.
[18] E. Voest,et al. Reactive oxygen intermediates increase vascular endothelial growth factor expression in vitro and in vivo. , 1996, The Journal of clinical investigation.
[19] S. Ryan,et al. Subretinal neovascularization. Natural history of an experimental model. , 1982, Archives of ophthalmology.
[20] I. Hemo,et al. In vivo angiogenic activity of interleukins. , 1990, Archives of ophthalmology.
[21] J. Marshall,et al. Age-related variation in the hydraulic conductivity of Bruch's membrane. , 1995, Investigative ophthalmology & visual science.
[22] J. Grunwald,et al. Effect of aging on foveolar choroidal circulation. , 1998, Archives of ophthalmology.
[23] K. Bartz-Schmidt,et al. Consequences of verteporfin photodynamic therapy on choroidal neovascular membranes. , 2006, Archives of ophthalmology.
[24] J. Neitz,et al. Local cellular sources of apolipoprotein E in the human retina and retinal pigmented epithelium: implications for the process of drusen formation. , 2001, American journal of ophthalmology.
[25] J. Folkman,et al. Endostatin inhibits angiogenesis by stabilization of newly formed endothelial tubes , 2004, Angiogenesis.
[26] U. Schmidt-Erfurth,et al. Increased expression of vascular endothelial growth factor associated with accumulation of lipids in Bruch’s membrane of LDL receptor knockout mice , 2005, British Journal of Ophthalmology.
[27] Gerald Liew,et al. Ranibizumab for neovascular age-related macular degeneration. , 2007, The New England journal of medicine.
[28] Carine Munaut,et al. Matrix metalloproteinase-9 contributes to choroidal neovascularization. , 2002, The American journal of pathology.
[29] S. Shih,et al. Nonvascular role for VEGF: VEGFR-1, 2 activity is critical for neural retinal development. , 2001, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[30] D. Hinton,et al. Transdifferentiated retinal pigment epithelial cells are immunoreactive for vascular endothelial growth factor in surgically excised age-related macular degeneration-related choroidal neovascular membranes. , 1996, Investigative ophthalmology & visual science.
[31] T. Otsuji,et al. Expression of vascular endothelial growth factor and its receptor (KDR/flk-1) mRNA in experimental choroidal neovascularization. , 1999, Current eye research.
[32] K. Alitalo,et al. Structure, expression and receptor-binding properties of novel vascular endothelial growth factors. , 1999, Current topics in microbiology and immunology.
[33] M. Kéramidas,et al. Expression of VEGF and angiopoietins in subfoveal membranes from patients with age-related macular degeneration. , 2005, American journal of ophthalmology.
[34] C. Curcio,et al. Basal linear deposit and large drusen are specific for early age-related maculopathy. , 1999, Archives of ophthalmology.
[35] D. Connolly,et al. Vascular permeability factor: a tumor-derived polypeptide that induces endothelial cell and monocyte procoagulant activity, and promotes monocyte migration , 1990, The Journal of experimental medicine.
[36] D. Hinton,et al. Apoptosis in surgically excised choroidal neovascular membranes in age-related macular degeneration. , 1998, Archives of ophthalmology.
[37] K. Alitalo,et al. Vascular endothelial growth factor B, a novel growth factor for endothelial cells. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[38] P. Campochiaro,et al. Transgenic mice with increased expression of vascular endothelial growth factor in the retina: a new model of intraretinal and subretinal neovascularization. , 1997, The American journal of pathology.
[39] M. Yanoff,et al. Artificial senescence of bovine retinal pigment epithelial cells induced by near-ultraviolet in vitro , 1999, Mechanisms of Ageing and Development.
[40] M. Goebeler,et al. Chemokines in cutaneous wound healing , 2001, Journal of leukocyte biology.
[41] D. S. Mcleod,et al. Pigment epithelium-derived factor (PEDF) and vascular endothelial growth factor (VEGF) in aged human choroid and eyes with age-related macular degeneration. , 2006, Experimental eye research.
[42] W. Inhoffen,et al. Clinicopathological findings of choroidal neovascularisation following verteporfin photodynamic therapy , 2004, British Journal of Ophthalmology.
[43] C. Grimm,et al. Age-related Macular Degeneration THE LIPOFUSCIN COMPONENT N-RETINYL-N-RETINYLIDENE ETHANOLAMINE DETACHES PROAPOPTOTIC PROTEINS FROM MITOCHONDRIA AND INDUCES APOPTOSIS IN MAMMALIAN RETINAL PIGMENT EPITHELIAL CELLS * , 2009 .
[44] K. Alitalo,et al. Vascular endothelial growth factor D (VEGF-D) is a ligand for the tyrosine kinases VEGF receptor 2 (Flk1) and VEGF receptor 3 (Flt4). , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[45] A Kijlstra,et al. Polarized vascular endothelial growth factor secretion by human retinal pigment epithelium and localization of vascular endothelial growth factor receptors on the inner choriocapillaris. Evidence for a trophic paracrine relation. , 1999, The American journal of pathology.
[46] Joan W. Miller,et al. Expression of pigment epithelium-derived factor in experimental choroidal neovascularization. , 2002, Investigative ophthalmology & visual science.
[47] W. Roberts,et al. Monocyte-induced cytokine expression in cultured human retinal pigment epithelial cells. , 1995, Experimental eye research.
[48] J. Marshall,et al. Decreasing hydraulic conductivity of Bruch's membrane: relevance to photoreceptor survival and lipofuscinoses. , 1995, American journal of medical genetics.
[49] I J Constable,et al. Overexpression of vascular endothelial growth factor (VEGF) in the retinal pigment epithelium leads to the development of choroidal neovascularization. , 2000, The American journal of pathology.
[50] S. Temel,et al. Preclinical safety evaluation of intravitreal injection of full-length humanized vascular endothelial growth factor antibody in rabbit eyes. , 2007, Investigative ophthalmology & visual science.
[51] E. Rungger-Brändle,et al. Exocytic clearing of degraded membrane material from pigment epithelial cells in frog retina. , 1987, Investigative ophthalmology & visual science.
[52] D. Hinton,et al. Natural history of choroidal neovascularization induced by vascular endothelial growth factor in the primate , 2000, Graefe's Archive for Clinical and Experimental Ophthalmology.
[53] S. Russell,et al. Drusen associated with aging and age‐related macular degeneration contain proteins common to extracellular deposits associated with atherosclerosis, elastosis, amyloidosis, and dense deposit disease , 2000, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[54] P. Polverini,et al. Role of the macrophage in the positive and negative regulation of wound neovascularization. , 1993, Behring Institute Mitteilungen.
[55] B W Henderson,et al. Role of cytokines in photodynamic therapy-induced local and systemic inflammation , 2003, British Journal of Cancer.
[56] Lieve Moons,et al. Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele , 1996, Nature.
[57] P. Campochiaro,et al. Inhibition of choroidal neovascularization by intravenous injection of adenoviral vectors expressing secretable endostatin. , 2001, The American journal of pathology.
[58] Marina Ziche,et al. VEGF165b, an Inhibitory Vascular Endothelial Growth Factor Splice Variant , 2004, Cancer Research.
[59] K. Heimann,et al. Cellular transport of subretinal material into choroidal and scleral blood vessels: an electron microscopic study , 1999, Graefe's Archive for Clinical and Experimental Ophthalmology.
[60] Lois E. H. Smith,et al. Oxygen-induced retinopathy in the mouse. , 1994, Investigative ophthalmology & visual science.
[61] J. Folkman,et al. Hypoxic Induction of Endothelial Cell Growth Factors in Retinal Cells: Identification and Characterization of Vascular Endothelial Growth Factor (VEGF) as the Mitogen , 1995 .
[62] U. Felbor,et al. Generation and degradation of human endostatin proteins by various proteinases , 2000, FEBS letters.
[63] Yong Chul Lee. The involvement of VEGF in endothelial permeability: a target for anti-inflammatory therapy. , 2005, Current opinion in investigational drugs.
[64] E. Traboulsi. The challenges and surprises of studying the genetics of age-related macular degeneration. , 2005, American journal of ophthalmology.
[65] A. Adamis,et al. Requirement for vascular endothelial growth factor in wound- and inflammation-related corneal neovascularization. , 1998, Investigative ophthalmology & visual science.
[66] W R Green,et al. Age-related Macular Degeneration Histopathologic Studies: The 1992 Lorenz E. Zimmerman Lecture , 1993, Ophthalmology.
[67] W. Green,et al. Granulomatous reaction to Bruch's membrane in age-related macular degeneration. , 1994, Archives of ophthalmology.
[68] S. Ryan,et al. Activated macrophages in experimental subretinal neovascularization. , 1990, Ophthalmologica. Journal international d'ophtalmologie. International journal of ophthalmology. Zeitschrift fur Augenheilkunde.
[69] G. Palade,et al. Increased microvascular permeability and endothelial fenestration induced by vascular endothelial growth factor. , 1995, Journal of cell science.
[70] K. Bartz-Schmidt,et al. Expression of endostatin in human choroidal neovascular membranes secondary to age-related macular degeneration. , 2006, Experimental eye research.
[71] U. Schmidt-Erfurth,et al. Mechanisms of action of photodynamic therapy with verteporfin for the treatment of age-related macular degeneration. , 2000, Survey of ophthalmology.
[72] B. Olffson. Vascular endothelial grouth facter B, a novel growth facter for endothelial cells , 1996 .
[73] W R Green,et al. Senile macular degeneration: a histopathologic study. , 1977, Transactions of the American Ophthalmological Society.
[74] P. Sudhakaran,et al. 60K gelatinase involved in mammary gland involution is regulated by beta-oestradiol. , 1998, Biochimica et biophysica acta.
[75] L. Salamonsen. Matrix metalloproteinases and endometrial remodelling. , 1994, Cell biology international.
[76] P. Ratcliffe,et al. Regulation of angiogenesis by hypoxia: role of the HIF system , 2003, Nature Medicine.
[77] J. Rakic,et al. Placental growth factor, a member of the VEGF family, contributes to the development of choroidal neovascularization. , 2003, Investigative ophthalmology & visual science.
[78] Lois E. H. Smith,et al. Pigment epithelium-derived factor is a substrate for matrix metalloproteinase type 2 and type 9: implications for downregulation in hypoxia. , 2005, Investigative ophthalmology & visual science.
[79] H. Grossniklaus,et al. Macrophage and retinal pigment epithelium expression of angiogenic cytokines in choroidal neovascularization. , 2002, Molecular vision.
[80] H. Kaplan,et al. Role of Complement and Complement Membrane Attack Complex in Laser-Induced Choroidal Neovascularization1 , 2005, The Journal of Immunology.
[81] G. Viglietto,et al. Isolation of a human placenta cDNA coding for a protein related to the vascular permeability factor. , 1991, Proceedings of the National Academy of Sciences of the United States of America.
[82] Joan W. Miller,et al. Prevention of experimental choroidal neovascularization with intravitreal anti-vascular endothelial growth factor antibody fragment. , 2002, Archives of ophthalmology.
[83] R. Timpl,et al. Structure, function and tissue forms of the C‐terminal globular domain of collagen XVIII containing the angiogenesis inhibitor endostatin , 1998, The EMBO journal.
[84] J. Levy,et al. Consequences of the photodynamic treatment of resting and activated peripheral T lymphocytes. , 1999, Immunopharmacology.
[85] M. Boulton,et al. RPE lipofuscin and its role in retinal pathobiology. , 2005, Experimental eye research.
[86] Sonia H Yoo,et al. Age-related macular degeneration: etiology, pathogenesis, and therapeutic strategies. , 2003, Survey of ophthalmology.
[87] D. S. Mcleod,et al. Quantifying changes in RPE and choroidal vasculature in eyes with age-related macular degeneration. , 2002, Investigative ophthalmology & visual science.
[88] M. Moschos,et al. Intravitreal use of bevacizumab (Avastin) for choroidal neovascularization due to ARMD: a preliminary multifocal-ERG and OCT study , 2007, Documenta Ophthalmologica.
[89] N. Ferrara,et al. The biology of VEGF and its receptors , 2003, Nature Medicine.
[90] J. Grunwald,et al. Changes in Choriocapillaris and Retinal Pigment Epithelium ( RPE ) in Age-Related Macular Degeneration , 1999 .
[91] P. Campochiaro,et al. AAV-mediated gene transfer of pigment epithelium-derived factor inhibits choroidal neovascularization. , 2002, Investigative ophthalmology & visual science.
[92] R. D'Amato,et al. Regulation of Vascular Endothelial Growth Factor Expression by Insulin-Like Growth Factor I , 1997, Diabetes.
[93] M. Ellersieck,et al. Age-related changes in the ultrastructure of Bruch's membrane. , 1985, American journal of ophthalmology.
[94] P. Campochiaro. Ocular neovascularisation and excessive vascular permeability , 2004, Expert opinion on biological therapy.
[95] R Birngruber,et al. Photodynamic therapy with verteporfin for choroidal neovascularization caused by age-related macular degeneration: results of retreatments in a phase 1 and 2 study. , 1999, Archives of ophthalmology.
[96] H. Dvorak,et al. Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. , 1995, The American journal of pathology.
[97] D. Connolly,et al. Tumor vascular permeability factor stimulates endothelial cell growth and angiogenesis. , 1989, The Journal of clinical investigation.
[98] P. Linsley,et al. Comparative analysis of B7-1 and B7-2 costimulatory ligands: expression and function , 1994, The Journal of experimental medicine.
[99] W. Freeman,et al. Preventive versus treatment effect of AG3340, a potent matrix metalloproteinase inhibitor in a rat model of choroidal neovascularization. , 2004, Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics.
[100] Georg Breier,et al. Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo , 1992, Nature.
[101] C. Cetrulo,et al. Endostatin Inhibits Ischemia-Induced Neovascularization and Increases Ischemic Tissue Loss , 2004, Annals of plastic surgery.
[102] P. Campochiaro,et al. Periocular gene transfer of pigment epithelium-derived factor inhibits choroidal neovascularization in a human-sized eye. , 2005, Human gene therapy.
[103] A. Camargo,et al. Collagen XVIII, containing an endogenous inhibitor of angiogenesis and tumor growth, plays a critical role in the maintenance of retinal structure and in neural tube closure (Knobloch syndrome). , 2000, Human molecular genetics.
[104] R. Schlingemann. Role of growth factors and the wound healing response in age-related macular degeneration , 2003, Graefe's Archive for Clinical and Experimental Ophthalmology.
[105] U. Schmidt-Erfurth,et al. Sequence of early vascular events after photodynamic therapy. , 2003, Investigative ophthalmology & visual science.
[106] Kenneth D Anderson,et al. Inhibition of retinal and choroidal neovascularization by a novel KDR kinase inhibitor. , 2005, Molecular vision.
[107] Lois E. H. Smith,et al. Vascular endothelial growth factor/vascular permeability factor expression in a mouse model of retinal neovascularization. , 1995, Proceedings of the National Academy of Sciences of the United States of America.
[108] L. Aiello,et al. Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF-receptor chimeric proteins. , 1995, Proceedings of the National Academy of Sciences of the United States of America.
[109] P. Wiedemann,et al. Histological findings of surgically excised choroidal neovascular membranes after photodynamic therapy , 2001, The British journal of ophthalmology.
[110] K. Nakagawa,et al. Expression of vascular endothelial growth factor in experimental choroidal neovascularization , 1997, Graefe's Archive for Clinical and Experimental Ophthalmology.
[111] P. Campochiaro,et al. Cell injury unmasks a latent proangiogenic phenotype in mice with increased expression of FGF2 in the retina , 2000, Journal of cellular physiology.
[112] J D Gass,et al. Drusen and disciform macular detachment and degeneration. , 1973, Archives of ophthalmology.
[113] D. Connolly,et al. Vascular permeability factor, an endothelial cell mitogen related to PDGF. , 1989, Science.
[114] K. Bartz-Schmidt,et al. INFLUENCE OF VERTEPORFIN PHOTODYNAMIC THERAPY ON INFLAMMATION IN HUMAN CHOROIDAL NEOVASCULAR MEMBRANES SECONDARY TO AGE-RELATED MACULAR DEGENERATION , 2007, Retina.
[115] Y. Ohnishi,et al. Formation of drusen in the human eye. , 1986, American journal of ophthalmology.
[116] K. Bartz-Schmidt,et al. Effect of verteporfin photodynamic therapy on endostatin and angiogenesis in human choroidal neovascular membranes , 2006, British Journal of Ophthalmology.
[117] J. Folkman,et al. Synthesis and secretion of vascular permeability factor/vascular endothelial growth factor by human retinal pigment epithelial cells. , 1993, Biochemical and biophysical research communications.
[118] S. Seregard,et al. Matrix metalloproteinases and metalloproteinase inhibitors in choroidal neovascular membranes. , 1998, Investigative ophthalmology & visual science.
[119] D. Eliott,et al. Basic fibroblast growth factor and vascular endothelial growth factor are present in epiretinal and choroidal neovascular membranes. , 1996, American journal of ophthalmology.
[120] C. Curcio. Photoreceptor topography in ageing and age-related maculopathy , 2001, Eye.
[121] D. Maglione. Persico MG.Isolation of a human placenta cDNA coding for a potein related to the vascular premeability factor , 1991 .
[122] M. Killingsworth. Age-related components of Bruch's membrane in the human eye , 2006, Graefe's Archive for Clinical and Experimental Ophthalmology.
[123] G. Viglietto,et al. Two alternative mRNAs coding for the angiogenic factor, placenta growth factor (PlGF), are transcribed from a single gene of chromosome 14. , 1993, Oncogene.
[124] U. Schmidt-Erfurth,et al. Histopathological changes following photodynamic therapy in human eyes. , 2002, Archives of ophthalmology.
[125] B. Kuehn. Gene discovery provides clues to cause of age-related macular degeneration. , 2005, JAMA.
[126] L. V. Johnson,et al. Complement activation and inflammatory processes in Drusen formation and age related macular degeneration. , 2001, Experimental eye research.
[127] U. Schmidt-Erfurth,et al. Changes in confocal indocyanine green angiography through two years after photodynamic therapy with verteporfin. , 2003, Ophthalmology.
[128] J. J. Plantner,et al. Increase in interphotoreceptor matrix gelatinase A (MMP-2) associated with age-related macular degeneration. , 1998, Experimental eye research.
[129] E. Rodriguez-Boulan,et al. The lipofuscin component A2E selectively inhibits phagolysosomal degradation of photoreceptor phospholipid by the retinal pigment epithelium , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[130] S M Meyers,et al. A twin study of age-related macular degeneration. , 1995, American journal of ophthalmology.
[131] A. Kijlstra,et al. REVIEW ARTICLE, Immunological Factors in the Pathogenesis and Treatment of Age-Related Macular Degeneration , 2005, Ocular immunology and inflammation.
[132] David J. Wilson,et al. Histopathologic and ultrastructural features of surgically excised subfoveal choroidal neovascular lesions: submacular surgery trials report no. 7. , 2005 .
[133] W. Manning,et al. AAV-mediated expression of vascular endothelial growth factor induces choroidal neovascularization in rat. , 2003, Investigative ophthalmology & visual science.
[134] U. Schmidt-Erfurth,et al. Photodynamic effects on choroidal neovascularization and physiological choroid. , 2002, Investigative ophthalmology & visual science.
[135] Arne Skerra,et al. Anticalins as alternative binding proteins for therapeutic use. , 2007, Current opinion in molecular therapeutics.
[136] T. Salo,et al. Generation of biologically active endostatin fragments from human collagen XVIII by distinct matrix metalloproteases. , 2005, Experimental cell research.
[137] N. Fukai,et al. Lack of collagen XVIII/endostatin results in eye abnormalities , 2002, The EMBO journal.
[138] Peter K. Kaiser,et al. ANCHOR STUDY GROUP. RANIBIZUMAB VERSUS VERTEPORFIN FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION , 2006 .
[139] R. Frank,et al. Growth factor localization in choroidal neovascular membranes of age-related macular degeneration. , 1994, Investigative ophthalmology & visual science.
[140] H. Grossniklaus,et al. Pathologic features of surgically excised subretinal neovascular membranes in age-related macular degeneration. , 1991, American journal of ophthalmology.
[141] R. Nicosia,et al. Regulation of Vascular Growth and Regression by Matrix Metalloproteinases in the Rat Aorta Model of Angiogenesis , 2000, Laboratory Investigation.
[142] U. Felbor,et al. Collagen XVIII/endostatin structure and functional role in angiogenesis. , 2000, Cell structure and function.
[143] Noam Brown,et al. Microenvironmental influence on macrophage regulation of angiogenesis in wounds and malignant tumors , 2001, Journal of leukocyte biology.
[144] Joyce Tombran-Tink,et al. Expression of pigment epithelium-derived factor in normal adult rat eye and experimental choroidal neovascularization. , 2002, Investigative ophthalmology & visual science.
[145] Kenneth P. Roos,et al. Autocrine VEGF Signaling Is Required for Vascular Homeostasis , 2007, Cell.
[146] R. Kuijpers,et al. Insulin-like growth factor-I and its receptor in neovascular age-related macular degeneration. , 2003, Investigative ophthalmology & visual science.
[147] K. Bartz-Schmidt,et al. Effects of bevacizumab on retinal function in isolated vertebrate retina , 2006, British Journal of Ophthalmology.
[148] P Sternberg,et al. Well-defined subfoveal choroidal neovascular membranes in age-related macular degeneration. , 1993, Ophthalmology.
[149] D. Wilson,et al. Choroidal neovascularization. , 1986, Ophthalmology.
[150] A. Reiner,et al. Vascular endothelial growth factor increases release of gelatinase A and decreases release of tissue inhibitor of metalloproteinases by microvascular endothelial cells in vitro. , 1998, Microvascular research.
[151] R. Kendall,et al. Inhibition of vascular endothelial cell growth factor activity by an endogenously encoded soluble receptor. , 1993, Proceedings of the National Academy of Sciences of the United States of America.
[152] J. Hamada,et al. Hypoxia suppresses the production of matrix metalloproteinases and the migration of humanmonocyte‐derived dendritic cells , 2005, European journal of immunology.
[153] Joan W. Miller,et al. VEGF164-mediated Inflammation Is Required for Pathological, but Not Physiological, Ischemia-induced Retinal Neovascularization , 2003, The Journal of experimental medicine.
[154] Min Zhang,et al. Effects of endostatin-vascular endothelial growth inhibitor chimeric recombinant adenoviruses on antiangiogenesis. , 2004, World journal of gastroenterology.
[155] K. Alitalo,et al. A novel vascular endothelial growth factor, VEGF‐C, is a ligand for the Flt4 (VEGFR‐3) and KDR (VEGFR‐2) receptor tyrosine kinases. , 1996, The EMBO journal.
[156] T J Flotte,et al. Verteporfin photodynamic therapy retreatment of normal retina and choroid in the cynomolgus monkey. , 1999, Ophthalmology.
[157] J. Tuo,et al. Genetic factors of age-related macular degeneration , 2004, Progress in Retinal and Eye Research.
[158] Harold Snieder,et al. Genetic influence on early age-related maculopathy: a twin study. , 2002, Ophthalmology.
[159] David T. Shima,et al. Vascular endothelial growth factor-A is a survival factor for retinal neurons and a critical neuroprotectant during the adaptive response to ischemic injury. , 2007, The American journal of pathology.
[160] M. Matsumura,et al. Exocytosis by retinal pigment epithelial cells. , 1985, Ophthalmic Research.
[161] T. Hisatomi,et al. The critical role of ocular‐infiltrating macrophages in the development of choroidal neovascularization , 2003, Journal of leukocyte biology.
[162] Reginald Birngruber,et al. Photodynamic Therapy With Verteporfin for Choroidal Neovascularization Caused by Age-related Macular Degeneration: Results of a Single Treatment in a Phase 1 and 2 Study , 1999 .
[163] M. Cross,et al. Angiostatin and endostatin inhibit endothelial cell migration in response to FGF and VEGF without interfering with specific intracellular signal transduction pathways , 2003, FEBS letters.
[164] O. Volpert,et al. Pigment epithelium-derived factor is deficient in the vitreous of patients with choroidal neovascularization due to age-related macular degeneration. , 2002, American journal of ophthalmology.
[165] S. Shaw,et al. Thy-1, a novel marker for angiogenesis upregulated by inflammatory cytokines. , 1998, Circulation research.
[166] P. McGuire,et al. Retinal and choroidal angiogenesis: pathophysiology and strategies for inhibition , 2003, Progress in Retinal and Eye Research.
[167] K. Alitalo,et al. Altered expression patterns of VEGF receptors in human diabetic retina and in experimental VEGF-induced retinopathy in monkey. , 2002, Investigative ophthalmology & visual science.
[168] P. Campochiaro,et al. Pigment epithelium‐derived factor inhibits retinal and choroidal neovascularization , 2001, Journal of cellular physiology.
[169] Purushottam Jha,et al. Role of complement and complement membrane attack complex in laser-induced choroidal neovascularization. , 2005, Journal of immunology.
[170] S. Seregard,et al. Subfoveal fibrovascular membranes in age-related macular degeneration express vascular endothelial growth factor. , 1996, Investigative ophthalmology & visual science.
[171] K. Bartz-Schmidt,et al. Comparative antiproliferative and cytotoxic profile of bevacizumab (Avastin), pegaptanib (Macugen) and ranibizumab (Lucentis) on different ocular cells , 2007, Graefe's Archive for Clinical and Experimental Ophthalmology.
[172] W. Benedict,et al. Pigment epithelium-derived factor: a potent inhibitor of angiogenesis. , 1999, Science.
[173] W. Kaelin,et al. Negative regulation of hypoxia-inducible genes by the von Hippel-Lindau protein. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[174] L. Schook,et al. Mechanisms generating functionally heterogeneous macrophages: chaos revisited , 1993, Journal of leukocyte biology.
[175] Cord Sunderkötter,et al. Macrophages and angiogenesis , 1994, Journal of leukocyte biology.
[176] T. Sasaki,et al. Characterization of extracellular matrix components in the limbal epithelial stem cell compartment. , 2007, Experimental eye research.
[177] J. Ambati,et al. Macrophage depletion inhibits experimental choroidal neovascularization. , 2003, Investigative ophthalmology & visual science.
[178] Napoleone Ferrara,et al. Vascular endothelial growth factor: basic science and clinical progress. , 2004, Endocrine reviews.
[179] B. Henderson,et al. Altered expression of interleukin 6 and interleukin 10 as a result of photodynamic therapy in vivo. , 1997, Cancer research.
[180] W. Schaper,et al. Monocyte activation in angiogenesis and collateral growth in the rabbit hindlimb. , 1998, The Journal of clinical investigation.
[181] G. A. Limb,et al. Age-dependent variation in metalloproteinase activity of isolated human Bruch's membrane and choroid. , 1999, Investigative ophthalmology & visual science.
[182] I. Cree,et al. Multifocal choroiditis: clinicopathologic correlation. , 1998, Archives of ophthalmology.
[183] K. Bartz-Schmidt,et al. Expression of endoglin in choroidal neovascularization. , 2004, Experimental eye research.
[184] H. Grossniklaus,et al. Ultrastructural features of surgically excised subretinal neovascular membranes in the ocular histoplasmosis syndrome. , 1993, Archives of ophthalmology.
[185] N. Bressler,et al. Photodynamic therapy with verteporfin (Visudyne): impact on ophthalmology and visual sciences. , 2000, Investigative ophthalmology & visual science.
[186] P. Campochiaro,et al. Retinal and choroidal neovascularization , 2000, Journal of cellular physiology.
[187] Susan Schneider,et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. , 2006, The New England journal of medicine.
[188] D. Mukhopadhyay,et al. Ligation of CD40 induces the expression of vascular endothelial growth factor by endothelial cells and monocytes and promotes angiogenesis in vivo. , 2000, Blood.
[189] J. Weiter,et al. Cell loss in the aging retina. Relationship to lipofuscin accumulation and macular degeneration. , 1989, Investigative ophthalmology & visual science.
[190] G. Peyman,et al. TESTING INTRAVITREAL TOXICITY OF BEVACIZUMAB (AVASTIN) , 2006, Retina.
[191] M. Nishida,et al. Hypoxia simultaneously inhibits endostatin production and stimulates vascular endothelial growth factor production by cultured human endometrial stromal cells. , 2004, Fertility and sterility.
[192] K. Csaky,et al. Monocyte activation in patients with age-related macular degeneration: a biomarker of risk for choroidal neovascularization? , 2004, Archives of ophthalmology.
[193] S. Itohara,et al. Reduced choroidal neovascular membrane formation in matrix metalloproteinase-2-deficient mice. , 2003, Investigative ophthalmology & visual science.
[194] W. Inhoffen,et al. Immunohistopathologic evaluation of choroidal neovascular membranes following verteporfin-photodynamic therapy. , 2004, American journal of ophthalmology.
[195] F. A. Shamsi,et al. Inhibition of RPE lysosomal and antioxidant activity by the age pigment lipofuscin. , 2001, Investigative ophthalmology & visual science.
[196] N. Ferrara. Vascular endothelial growth factor: molecular and biological aspects. , 1999, Current topics in microbiology and immunology.
[197] D. K. Wilcox. Vectorial accumulation of cathepsin D in retinal pigmented epithelium: effects of age. , 1988, Investigative ophthalmology & visual science.
[198] Alan W. Stitt,et al. Expression of vascular endothelial growth factor (VEGF) and its receptors is regulated in eyes with intra‐ocular tumours , 1998, The Journal of pathology.
[199] K. Sonoda,et al. The relative contributions of each subset of ocular infiltrated cells in experimental choroidal neovascularisation , 2004, British Journal of Ophthalmology.
[200] U. Brunk,et al. Lipofuscin accumulation in cultured retinal pigment epithelial cells reduces their phagocytic capacity. , 1998, Current eye research.
[201] Philip Hahnfeldt,et al. Combined therapy with direct and indirect angiogenesis inhibition results in enhanced antiangiogenic and antitumor effects. , 2003, Cancer research.
[202] D. Connolly,et al. Human vascular permeability factor. Isolation from U937 cells. , 1989, The Journal of biological chemistry.
[203] M. Gillies,et al. Immunological and Aetiological Aspects of Macular Degeneration , 2001, Progress in Retinal and Eye Research.
[204] Carine Munaut,et al. MMP‐2 and MMP‐9 synergize in promoting choroidal neovascularization , 2003, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[205] R. Obata,et al. A novel vascular endothelial growth factor receptor 2 inhibitor, SU11248, suppresses choroidal neovascularization in vivo. , 2006, Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics.
[206] D. Bok. Evidence for an inflammatory process in age-related macular degeneration gains new support. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[207] Joan W. Miller,et al. Vascular endothelial growth factor/vascular permeability factor is temporally and spatially correlated with ocular angiogenesis in a primate model. , 1994, The American journal of pathology.
[208] Tiansen Li,et al. Collagen XVIII/endostatin is essential for vision and retinal pigment epithelial function , 2004, The EMBO journal.
[209] K. Bartz-Schmidt,et al. Matrix metalloproteinases in human choroidal neovascular membranes excised following verteporfin photodynamic therapy , 2007, British Journal of Ophthalmology.
[210] D. Goeddel,et al. Vascular endothelial growth factor is a secreted angiogenic mitogen. , 1989, Science.
[211] L. Devy,et al. The antitumoral effect of endostatin and angiostatin is associated with a down‐regulation of vascular endothelial growth factor expression in tumor cells , 2002, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[212] R. Frank,et al. Ulrastructural Immunocytochemistry of Subretinal Neovascular Membranes in Age-related Macular Degeneration , 1992 .
[213] M. Killingsworth,et al. Macrophages related to Bruch's membrane in age-related macular degeneration , 1990, Eye.
[214] K. Csaky,et al. Macrophage depletion diminishes lesion size and severity in experimental choroidal neovascularization. , 2003, Investigative ophthalmology & visual science.
[215] E. Friedman,et al. The role of the atherosclerotic process in the pathogenesis of age-related macular degeneration. , 2000, American journal of ophthalmology.
[216] P. Speight,et al. Photodynamic therapy of normal rat arteries after photosensitisation using disulphonated aluminium phthalocyanine and 5-aminolaevulinic acid. , 1994, British Journal of Cancer.
[217] L. Feeney-Burns,et al. Aging human RPE: morphometric analysis of macular, equatorial, and peripheral cells. , 1984, Investigative ophthalmology & visual science.
[218] E S Gragoudas,et al. Inhibition of vascular endothelial growth factor prevents retinal ischemia-associated iris neovascularization in a nonhuman primate. , 1996, Archives of ophthalmology.
[219] A Hofman,et al. Genetic risk of age-related maculopathy. Population-based familial aggregation study. , 1998, Archives of ophthalmology.
[220] J. Keiser,et al. Vascular endothelial growth factor upregulates the expression of matrix metalloproteinases in vascular smooth muscle cells: role of flt-1. , 1998, Circulation research.
[221] R Birngruber,et al. Photodynamic therapy with verteporfin for choroidal neovascularization caused by age-related macular degeneration: results of a single treatment in a phase 1 and 2 study. , 1999, Archives of ophthalmology.
[222] V. Vincenti,et al. Structure, expression and receptor-binding properties of placenta growth factor (PlGF). , 1999, Current topics in microbiology and immunology.
[223] Joan W. Miller,et al. Expression of leukocyte adhesion molecules in human subfoveal choroidal neovascular membranes treated with and without photodynamic therapy. , 2004, Investigative ophthalmology & visual science.
[224] J. Piette,et al. Downregulation of ICAM-1 and VCAM-1 expression in endothelial cells treated by photodynamic therapy , 2004, Oncogene.
[225] W. Inhoffen,et al. Verteporfin photodynamic therapy induced apoptosis in choroidal neovascular membranes , 2006, British Journal of Ophthalmology.
[226] P Sternberg,et al. Immunohistochemical and histochemical properties of surgically excised subretinal neovascular membranes in age-related macular degeneration. , 1992, American journal of ophthalmology.
[227] A. Harris,et al. Cytokine networks in solid human tumors: regulation of angiogenesis , 1994, Journal of leukocyte biology.
[228] A. Mcneilly,et al. The effect of luteal "rescue" on the expression and localization of matrix metalloproteinases and their tissue inhibitors in the human corpus luteum. , 1998, The Journal of clinical endocrinology and metabolism.
[229] Kenneth J. Hillan,et al. Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene , 1996, Nature.
[230] D. Bok,et al. Expression, secretion, and age-related downregulation of pigment epithelium-derived factor, a serpin with neurotrophic activity , 1995, The Journal of neuroscience : the official journal of the Society for Neuroscience.
[231] P T de Jong,et al. Morphometric analysis of Bruch's membrane, the choriocapillaris, and the choroid in aging. , 1994, Investigative ophthalmology & visual science.
[232] S. Kondo,et al. Significance of vascular endothelial growth factor/vascular permeability factor for solid tumor growth, and its inhibition by the antibody. , 1993, Biochemical and biophysical research communications.
[233] P. Wiedemann,et al. MMP-2 AND MMP-9 SECRETION BY RPE IS STIMULATED BY ANGIOGENIC MOLECULES FOUND IN CHOROIDAL NEOVASCULAR MEMBRANES , 2006, Retina.
[234] Jennifer I. Lim,et al. Neuropilin-1 expression by endothelial cells and retinal pigment epithelial cells in choroidal neovascular membranes. , 2005, American journal of ophthalmology.
[235] M. Brantley,et al. SAFETY OF INTRAVITREAL INJECTION OF BEVACIZUMAB IN RABBIT EYES , 2006, Retina.
[236] H. Yamamoto,et al. Hypoxia down-regulates endostatin production by human microvascular endothelial cells and pericytes. , 2001, Biochemical and biophysical research communications.
[237] P. D'Amore,et al. Mechanisms of retinal and choroidal neovascularization. , 1994, Investigative ophthalmology & visual science.
[238] S. E. Barker,et al. EIAV vector-mediated delivery of endostatin or angiostatin inhibits angiogenesis and vascular hyperpermeability in experimental CNV , 2006, Gene Therapy.
[239] G. Seigel,et al. EVALUATION OF IN VITRO EFFECTS OF BEVACIZUMAB (AVASTIN) ON RETINAL PIGMENT EPITHELIAL, NEUROSENSORY RETINAL, AND MICROVASCULAR ENDOTHELIAL CELLS , 2006, Retina.
[240] E. Friedman. A hemodynamic model of the pathogenesis of age-related macular degeneration. , 1997, American journal of ophthalmology.
[241] M. Komada,et al. Vascular endothelial growth factor expression in choroidal neovascularization in rats , 1997, Graefe's Archive for Clinical and Experimental Ophthalmology.
[242] M. Blumenkranz,et al. Clinicopathologic study after submacular removal of choroidal neovascular membranes treated with verteporfin ocular photodynamic therapy. , 2003, American journal of ophthalmology.
[243] Xiangping Liu,et al. Matrix metalloproteinases expression in choroidal neovascular membranes. , 2004, Yan ke xue bao = Eye science.
[244] D. Anthony,et al. Histopathology and vascular endothelial growth factor in untreated and diode laser-treated retinopathy of prematurity. , 1997, Journal of AAPOS : the official publication of the American Association for Pediatric Ophthalmology and Strabismus.
[245] T. Veenstra,et al. Anti-angiogenic activity of human endostatin is HIF-1-independent in vitro and sensitive to timing of treatment in a human saphenous vein assay. , 2003, Molecular cancer therapeutics.
[246] D. Rifkin,et al. Plasminogen activators and matrix metalloproteinases in angiogenesis. , 1996, Enzyme & protein.
[247] M. Boulton,et al. Blue light-induced reactivity of retinal age pigment. In vitro generation of oxygen-reactive species. , 1995, The Journal of biological chemistry.
[248] E. Gragoudas,et al. Pegaptanib for neovascular age-related macular degeneration. , 2004, The New England journal of medicine.
[249] W. Green,et al. CLINICOPATHOLOGIC STUDIES OF AGE-RELATED MACULAR DEGENERATION WITH CLASSIC SUBFOVEAL CHOROIDAL NEOVASCULARIZATION TREATED WITH PHOTODYNAMIC THERAPY , 2001, Retina.
[250] U. Schmidt-Erfurth,et al. Influence of photodynamic therapy on expression of vascular endothelial growth factor (VEGF), VEGF receptor 3, and pigment epithelium-derived factor. , 2003, Investigative ophthalmology & visual science.
[251] P. Heiduschka,et al. Ultrastructural findings in the primate eye after intravitreal injection of bevacizumab. , 2007, American journal of ophthalmology.
[252] P. Campochiaro,et al. VEGF is major stimulator in model of choroidal neovascularization. , 2000, Investigative ophthalmology & visual science.
[253] P. Campochiaro,et al. A phase I trial of an IV-administered vascular endothelial growth factor trap for treatment in patients with choroidal neovascularization due to age-related macular degeneration. , 2006, Ophthalmology.
[254] K. Bartz-Schmidt,et al. Expression of VEGF and PEDF in choroidal neovascular membranes following verteporfin photodynamic therapy. , 2006, American journal of ophthalmology.
[255] Ivana K. Kim,et al. Constitutive expression of VEGF, VEGFR-1, and VEGFR-2 in normal eyes. , 1999, Investigative ophthalmology & visual science.
[256] K. Dutt,et al. Vasculotropin/Vascular endothelial growth factor is an autocrine growth factor for human retinal pigment epithelial cells cultued in vitro , 1995, Journal of cellular physiology.
[257] J. Bennett,et al. Inhibition of retinal neovascularization by intraocular viral-mediated delivery of anti-angiogenic agents. , 2002, Molecular therapy : the journal of the American Society of Gene Therapy.
[258] G. Neufeld,et al. Interleukin 6 Induces the Expression of Vascular Endothelial Growth Factor (*) , 1996, The Journal of Biological Chemistry.
[259] H. Shepard,et al. Macrophage-induced angiogenesis is mediated by tumour necrosis factor-α , 1987, Nature.
[260] M. Boulton,et al. The role of oxidative stress in the pathogenesis of age-related macular degeneration. , 2000, Survey of ophthalmology.
[261] Marco A Zarbin,et al. Current concepts in the pathogenesis of age-related macular degeneration. , 2004, Archives of ophthalmology.
[262] J. Mulliken,et al. The role of matrix metalloproteinase activity in the maturation of human capillary endothelial cells in vitro. , 1999, Journal of cell science.
[263] Andreas Wenzel,et al. Age-related Macular Degeneration , 2000, The Journal of Biological Chemistry.
[264] Emmett T. Cunningham,et al. VEGF INHIBITION STUDY IN OCULAR NEOVASCULARIZATION CLINICAL TRIAL GROUP. PEGAPTANIB FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION , 2004 .
[265] W. Kaelin,et al. HIF hydroxylation and the mammalian oxygen-sensing pathway. , 2003, The Journal of clinical investigation.
[266] K. Suzuma,et al. The potential angiogenic role of macrophages in the formation of choroidal neovascular membranes. , 1999, Investigative ophthalmology & visual science.
[267] I. Morita,et al. Novel mechanism for age‐related macular degeneration: An equilibrium shift between the angiogenesis factors VEGF and PEDF , 2001, Journal of cellular physiology.
[268] M. Cooper,et al. Vascular endothelial growth factor and its receptors in control and diabetic rat eyes. , 1998, Laboratory investigation; a journal of technical methods and pathology.
[269] R. Frank,et al. Ultrastructural immunocytochemistry of subretinal neovascular membranes in age-related macular degeneration. , 1992, Ophthalmology.
[270] M. Shibuya,et al. The vascular endothelial growth factor (VEGF)/VEGF receptor system and its role under physiological and pathological conditions. , 2005, Clinical science.
[271] Roche ResearchCenter,et al. Vascular Permeability Factor: A Tumor-derived Polypeptide that Induces Endothelial Cell and Monocyte Procoagulant Activity, and Promotes Monocyte Migration , 1990 .
[272] H. Bitterman,et al. Hypoxia reduces the output of matrix metalloproteinase‐9 (MMP‐9) in monocytes by inhibiting its secretion and elevating membranal association , 2006, Journal of leukocyte biology.
[273] P. D’Amore. Vascular endothelial cell growth factor-a: not just for endothelial cells anymore. , 2007, The American journal of pathology.